ArticleEClinicalMedicine2026
The global landscape of cancer burden attributable to tobacco smoking in 2022: a population-based systematic analysis.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tobacco smoking is the most modifiable risk factor significantly contributing to the global cancer burden. Quantification of tobacco smoking-related cancer burden is essential for guiding future cancer prevention and control policy development. Methods: We used smoking prevalence data obtained from national surveys and relative risks for smoking-associated cancers extracted from high-quality published studies to calculate population attributable fractions (PAFs). We then aggregated PAFs and cancer incidence and mortality data from GLOBOCAN 2022 to estimate age-standardized incidence and mortality rates (ASIRs and ASMRs) attributable to smoking. We also compared cancer ASIRs and ASMRs between never-smokers and smokers. Findings: In 2022, estimates indicated that globally, 2,723,853 new cancer cases and 1,800,642 cancer-related deaths among individuals aged 20 years and above could be attributed to tobacco smoking, corresponding to PAFs of 14.76% (95% CI: 11.90%-17.17%) and 18.84% (95% CI: 15.22%-21.88%), respectively. Overall, males demonstrated substantially higher PAFs than females (incidence: 23.52% vs. 5.66%; mortality: 27.93% vs. 7.40%). However, for males, the highest PAF was observed in regions with a high Human Development Index (HDI), whereas for females, it peaked in regions with a very high HDI. Laryngeal exhibited the highest PAFs, followed by lung, bladder, esophageal, and oral cavity & pharyngeal cancers. However, lung cancer accounted for the largest proportion of smoking-related cancer cases (males 43.30%; females 49.97%) and deaths (males 50.04%; females 55.07%) worldwide. In higher-HDI regions, lung cancer contributed to nearly half of the smoking-related cancer burden (ranging from 45.08% to 63.25% across sexes for cases and deaths). Conversely, in lower-HDI regions, the burden was predominantly driven by oral cavity & pharyngeal, esophageal, and cervical cancers. In Eastern Asia, while the ASIRs and ASMRs of lung cancer among smokers were not globally the highest, the ASIRs (males: 39.04 per 100,000; females: 43.67 per 100,000) and ASMRs (males: 28.92 per 100,000; females: 20.86 per 100,000) among never-smokers in this region exceeded those in other geographical areas. Interpretation: Future efforts must therefore integrate aggressive, context-specific tobacco control into the core of cancer prevention strategies while prioritizing research into the unique risk factors driving lung cancer among never-smokers, particularly in high-burden populations such as Asian females. Funding: Capital's Funds for Health Improvement and Research (CFH2024-2G-40214), the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-011), National High Level Hospital Clinical Research Funding (2025-LYZX-R-A03), and 2023 Special Survey on Science and Technology Basic Resources (2023FY100605).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.